Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 150Colorectal Neoplasms 82Stomach Neoplasms 77Neoplasms 35Neoplasm Metastasis 35Pancreatic Neoplasms 25Triple Negative Breast Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 16Adenocarcinoma 13Esophageal Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colonic Neoplasms 10Biliary Tract Neoplasms 10Rectal Neoplasms 9Carcinoma, Hepatocellular 9Brain Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Adenocarcinoma Of Esophagus 7Solid Tumor 6Ovarian Neoplasms 6Cholangiocarcinoma 6Nasopharyngeal Carcinoma 5Gastrointestinal Neoplasms 5Esophageal Squamous Cell Carcinoma 5Recurrence 4Nasopharyngeal Neoplasms 4Advanced Solid Tumors 4Sarcoma 3Melanoma 3Head and Neck Neoplasms 3

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HER-2 Gene Amplification × Capecitabine × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡